Targeting B7-H3 to treat advanced prostate cancer
Official title: Novel Approaches Targeting B7-H3 in Castration-resistant Prostate Cancer
Funded at University of Tx Md Anderson Can Ctr · NIH-11001836 · Data updated 2026-11-12
This study is looking at how a protein called B7-H3 affects advanced prostate cancer that doesn't respond to regular hormone treatments, with the goal of finding better, more personalized therapies for patients with certain genetic changes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | January 1, 2023 |
| Project end | December 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $588,065 |
| NIH project number | 5R01CA275990-03 |
| Project ID | NIH-11001836 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with metastatic castration-resistant prostate cancer, particularly those with PTEN and TP53 gene mutations.
✕Less likely to help
Patients with early-stage prostate cancer or those without the specific genetic mutations being targeted may not benefit from this research.
What this research studies
This research investigates the role of B7-H3 signaling in advanced prostate cancer, particularly in cases that are resistant to standard hormone therapies. By understanding how B7-H3 contributes to cancer progression and immune evasion, the researchers aim to develop targeted therapies that could improve treatment outcomes for patients with specific genetic mutations. The study utilizes advanced models to explore the effects of B7-H3 depletion on tumor growth and the immune environment, potentially leading to new biomarker-driven treatment options.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for patients with castration-resistant prostate cancer, improving survival rates and quality of life.
How similar studies have gone: Previous research has shown promise in targeting similar pathways in cancer treatment, suggesting that this approach could yield significant advancements.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Zhao, Di — University of Tx Md Anderson Can Ctr
- Study coordinator: Zhao, Di
Related research
Other NIH-funded projects on the same topics.
-
Understanding how aggressive cell states emerge in castration-resistant prostate cancer
A research project aims to uncover the hidden cell states that help prostate cancer resist standard therapy and how these states arise early in tumor development.
-
Enhancer RNA CYP11A1-eRNA in castration-resistant prostate cancer
Researchers are testing a new RNA-based target, CYP11A1-eRNA, to see if blocking it can hamper the growth of castration-resistant prostate cancer in the lab and animal models.
-
Targeted Immunostimulatory Dual Drug Conjugates for Heterogeneous Metastatic Prostate Cancer
Researchers are testing a targeted therapy approach to help people with metastatic castration-resistant prostate cancer by boosting the immune system and delivering drugs directly to cancer cells.
-
Androgen Receptor Action in Prostate Cancer that Stops Responding to Therapy
This grant supports research to understand why certain prostate cancers stop responding to AR-targeted therapies and to find new ways to target them.
-
Hyperactive methylation in a hard-to-treat prostate cancer subtype
Researchers are studying a newly identified methylation-heavy group of advanced prostate cancer to understand its biology and find clues for better treatments.
-
Therapeutic Targeting of Lineage Plasticity in Advanced Prostate Cancer
A cancer research effort aimed at understanding and tackling how aggressive prostate cancers become resistant to standard AR-targeted therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.